DDInter268 DDInter1394
Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to (vitamin D3) in the skin, which is then converted to in the liver and kidneys. undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity. Calcitriol is considered to be the most potent metabolite of vitamin D in humans. Renal production of calcitriol is stimulated in response to PTH
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) resembles {v} (Compound) Cholecalciferol
Cholecalciferol {u} may lead to a major life threatening interaction when taken with {v} Paricalcitol
Calcitriol {u} (Compound) resembles {v} (Compound) Calcipotriol
Calcipotriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) resembles {v} (Compound) Dihydrotachysterol
Dihydrotachysterol {u} may lead to a major life threatening interaction when taken with {v} Paricalcitol
Calcitriol {u} (Compound) binds {v} (Gene) CYP24A1
CYP24A1 {u} (Gene) is bound by {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) is included by {v} (Pharmacologic Class) Cholecalciferol
Cholecalciferol {u} (Pharmacologic Class) includes {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) causes {v} (Side Effect) Taste metallic
Taste metallic {u} (Side Effect) is caused by {v} (Compound) Paricalcitol
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Paricalcitol
Calcitriol {u} (Compound) resembles {v} (Compound) Cholecalciferol
Cholecalciferol {u} (Compound) resembles {v} (Compound) Calcipotriol
Calcipotriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Calcitriol (Compound) resembles Paricalcitol (Compound)
Calcitriol (Compound) resembles Cholecalciferol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Calcitriol (Compound) resembles Calcipotriol (Compound) and Calcipotriol (Compound) resembles Paricalcitol (Compound)
Calcitriol (Compound) resembles Dihydrotachysterol (Compound) and Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol
Calcitriol (Compound) binds CYP24A1 (Gene) and CYP24A1 (Gene) is bound by Paricalcitol (Compound)
Calcitriol (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Paricalcitol (Compound)
Calcitriol (Compound) is included by Cholecalciferol (Pharmacologic Class) and Cholecalciferol (Pharmacologic Class) includes Paricalcitol (Compound)
Calcitriol (Compound) causes Taste metallic (Side Effect) and Taste metallic (Side Effect) is caused by Paricalcitol (Compound)
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol (Compound) resembles Paricalcitol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Calcitriol (Compound) resembles Cholecalciferol (Compound) and Cholecalciferol (Compound) resembles Calcipotriol (Compound) and Calcipotriol (Compound) resembles Paricalcitol (Compound)